Cargando…

Clinical usefulness of mepolizumab in severe eosinophilic asthma

Asthma is a chronic inflammatory disorder of the airways with variable clinical severity from very mild and occasional symptoms to recurrent critical exacerbations, at risk of fatal or near-fatal outcome, in a small percentage of patients. Within the different inflammatory cascades involved in asthm...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzella, Francesco, Lusuardi, Mirco, Montanari, Gloria, Galeone, Carla, Facciolongo, Nicola, Zucchi, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907717/
https://www.ncbi.nlm.nih.gov/pubmed/27354806
http://dx.doi.org/10.2147/TCRM.S86299
_version_ 1782437585239408640
author Menzella, Francesco
Lusuardi, Mirco
Montanari, Gloria
Galeone, Carla
Facciolongo, Nicola
Zucchi, Luigi
author_facet Menzella, Francesco
Lusuardi, Mirco
Montanari, Gloria
Galeone, Carla
Facciolongo, Nicola
Zucchi, Luigi
author_sort Menzella, Francesco
collection PubMed
description Asthma is a chronic inflammatory disorder of the airways with variable clinical severity from very mild and occasional symptoms to recurrent critical exacerbations, at risk of fatal or near-fatal outcome, in a small percentage of patients. Within the different inflammatory cascades involved in asthma, eosinophils play a central role in the pathogenesis and largely influence disease severity. Interleukin-5 (IL-5) is the main cytokine controlling eosinophil activity and proliferation at the site of inflammation. Mepolizumab was the first biological humanized anti-IL-5 monoclonal antibody tested in randomized clinical trials on eosinophilic asthma and other eosinophilic diseases. On the basis of several positive clinical efficacy data, it has recently been approved by the US Food and Drug Administration for the treatment of severe eosinophilic asthma. Unfortunately, high costs are at present a critical issue. Future studies will probably help in the correct selection of a potential “responder phenotype”, allowing the prescription of this promising therapy to appropriate patients and best define cost-effectiveness issues.
format Online
Article
Text
id pubmed-4907717
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49077172016-06-28 Clinical usefulness of mepolizumab in severe eosinophilic asthma Menzella, Francesco Lusuardi, Mirco Montanari, Gloria Galeone, Carla Facciolongo, Nicola Zucchi, Luigi Ther Clin Risk Manag Review Asthma is a chronic inflammatory disorder of the airways with variable clinical severity from very mild and occasional symptoms to recurrent critical exacerbations, at risk of fatal or near-fatal outcome, in a small percentage of patients. Within the different inflammatory cascades involved in asthma, eosinophils play a central role in the pathogenesis and largely influence disease severity. Interleukin-5 (IL-5) is the main cytokine controlling eosinophil activity and proliferation at the site of inflammation. Mepolizumab was the first biological humanized anti-IL-5 monoclonal antibody tested in randomized clinical trials on eosinophilic asthma and other eosinophilic diseases. On the basis of several positive clinical efficacy data, it has recently been approved by the US Food and Drug Administration for the treatment of severe eosinophilic asthma. Unfortunately, high costs are at present a critical issue. Future studies will probably help in the correct selection of a potential “responder phenotype”, allowing the prescription of this promising therapy to appropriate patients and best define cost-effectiveness issues. Dove Medical Press 2016-06-08 /pmc/articles/PMC4907717/ /pubmed/27354806 http://dx.doi.org/10.2147/TCRM.S86299 Text en © 2016 Menzella et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Menzella, Francesco
Lusuardi, Mirco
Montanari, Gloria
Galeone, Carla
Facciolongo, Nicola
Zucchi, Luigi
Clinical usefulness of mepolizumab in severe eosinophilic asthma
title Clinical usefulness of mepolizumab in severe eosinophilic asthma
title_full Clinical usefulness of mepolizumab in severe eosinophilic asthma
title_fullStr Clinical usefulness of mepolizumab in severe eosinophilic asthma
title_full_unstemmed Clinical usefulness of mepolizumab in severe eosinophilic asthma
title_short Clinical usefulness of mepolizumab in severe eosinophilic asthma
title_sort clinical usefulness of mepolizumab in severe eosinophilic asthma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907717/
https://www.ncbi.nlm.nih.gov/pubmed/27354806
http://dx.doi.org/10.2147/TCRM.S86299
work_keys_str_mv AT menzellafrancesco clinicalusefulnessofmepolizumabinsevereeosinophilicasthma
AT lusuardimirco clinicalusefulnessofmepolizumabinsevereeosinophilicasthma
AT montanarigloria clinicalusefulnessofmepolizumabinsevereeosinophilicasthma
AT galeonecarla clinicalusefulnessofmepolizumabinsevereeosinophilicasthma
AT facciolongonicola clinicalusefulnessofmepolizumabinsevereeosinophilicasthma
AT zucchiluigi clinicalusefulnessofmepolizumabinsevereeosinophilicasthma